Stock listing
HKEX:2509 Qyuns Therapeutics Co., Ltd. (荃信生物) 股價
Home listing (HKEX) of Qyuns Therapeutics Co., Ltd.
Follow Qyuns Therapeutics Co., Ltd. into a list and get an email when it puts out news.
Share price · HKEX:2509
$13.01 HKD -1.58 (-10.8%)
Close on Nov 20, 2026
- Day range
- $13.00 – $14.00 HKDNov 20, 2026
- Volume
- 26,200 sharesNov 20, 2026
- Market cap
- $2.91B HKDAt the close on Nov 20, 2026 · price × 223.4M shares outstanding
- 52-week range
- $13.00 – $24.50 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.75M HKDMedian day 42,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2509 · Home | $13.01 HKD | -1.58 (-10.8%) | 26,200 | $14.00 | $14.00 | $13.00 | $14.59 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2509 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.01 | -1.58 | -10.8% | $14.00 | $14.00 | $13.00 | 26,200 | |
| $14.59 | -0.01 | -0.1% | $14.60 | $14.60 | $14.59 | 1,200 | |
| $14.60 | +0.20 | +1.4% | $14.60 | $14.97 | $14.60 | 99,400 | |
| $14.40 | -0.30 | -2.0% | $14.42 | $14.56 | $14.40 | 30,000 | |
| $14.70 | -0.19 | -1.3% | $14.65 | $14.70 | $14.62 | 6,200 | |
| $14.89 | +0.28 | +1.9% | $14.99 | $15.30 | $14.72 | 17,000 | |
| $14.61 | -0.05 | -0.3% | $14.50 | $14.79 | $14.50 | 22,400 | |
| $14.66 | +0.16 | +1.1% | $14.52 | $14.70 | $14.41 | 24,000 | |
| $14.50 | +0.17 | +1.2% | $14.38 | $15.09 | $14.38 | 8,600 | |
| $14.33 | -0.47 | -3.2% | $16.00 | $16.00 | $14.33 | 124,140 | |
| $14.80 | -0.06 | -0.4% | $14.86 | $15.75 | $14.66 | 70,400 | |
| $14.86 | -0.14 | -0.9% | $14.68 | $15.13 | $13.78 | 144,600 | |
| $15.00 | -0.25 | -1.6% | $14.90 | $15.28 | $14.87 | 29,000 | |
| $15.25 | -0.05 | -0.3% | $15.80 | $15.80 | $14.80 | 23,800 | |
| $15.30 | 0.00 | 0.0% | $16.08 | $16.08 | $15.30 | 6,200 | |
| $15.30 | +0.12 | +0.8% | $15.80 | $15.80 | $14.86 | 87,800 | |
| $15.18 | -1.03 | -6.4% | $15.80 | $15.80 | $14.86 | 87,800 | |
| $16.21 | -0.39 | -2.3% | $16.38 | $16.64 | $15.70 | 768,600 | |
| $16.60 | +0.06 | +0.4% | $15.81 | $16.70 | $15.80 | 58,400 | |
| $16.54 | -0.02 | -0.1% | $16.07 | $16.60 | $16.07 | 58,400 | |
| $16.56 | -0.18 | -1.1% | $16.00 | $16.56 | $16.00 | 60,800 | |
| $16.74 | +0.54 | +3.3% | $16.20 | $16.74 | $15.87 | 42,800 | |
| $16.20 | +0.20 | +1.2% | $16.02 | $16.40 | $15.40 | 112,200 | |
| $16.00 | +0.50 | +3.2% | $15.84 | $16.67 | $15.48 | 638,000 | |
| $15.50 | -0.52 | -3.2% | $16.10 | $16.10 | $15.30 | 91,200 | |
| $16.02 | -0.40 | -2.4% | $16.39 | $16.61 | $16.02 | 615,000 | |
| $16.42 | -0.34 | -2.0% | $16.71 | $16.90 | $16.41 | 52,600 | |
| $16.76 | -0.24 | -1.4% | $17.00 | $17.10 | $16.62 | 250,000 | |
| $17.00 | 0.00 | 0.0% | $16.88 | $17.00 | $16.78 | 14,600 | |
| $17.00 | -0.29 | -1.7% | $16.95 | $17.12 | $16.80 | 26,200 | |
| $17.29 | -0.19 | -1.1% | $17.29 | $17.30 | $17.05 | 37,800 | |
| $17.48 | +0.10 | +0.6% | $17.38 | $17.78 | $17.21 | 127,400 | |
| $17.38 | +0.38 | +2.2% | $18.00 | $18.00 | $16.86 | 137,600 | |
| $17.00 | +0.05 | +0.3% | $16.79 | $17.20 | $16.79 | 34,200 | |
| $16.95 | +0.13 | +0.8% | $16.82 | $17.17 | $16.69 | 64,400 | |
| $16.82 | -0.35 | -2.0% | $16.82 | $16.84 | $16.82 | 1,000 | |
| $17.17 | +0.40 | +2.4% | $16.51 | $17.17 | $16.51 | 1,800 | |
| $16.77 | -0.11 | -0.7% | $16.63 | $16.96 | $16.41 | 23,800 | |
| $16.88 | -0.17 | -1.0% | $17.01 | $17.01 | $16.81 | 9,800 | |
| $17.05 | +0.05 | +0.3% | $17.58 | $17.63 | $16.72 | 68,400 | |
| $17.00 | +0.10 | +0.6% | $16.91 | $17.00 | $16.66 | 29,600 | |
| $16.90 | +0.15 | +0.9% | $17.24 | $17.50 | $16.66 | 44,800 | |
| $16.75 | +0.18 | +1.1% | $16.57 | $16.75 | $16.36 | 19,400 | |
| $16.57 | +0.12 | +0.7% | $16.40 | $16.60 | $16.40 | 3,000 | |
| $16.45 | -0.16 | -1.0% | $16.46 | $16.90 | $16.34 | 76,000 | |
| $16.61 | +0.08 | +0.5% | $16.45 | $16.80 | $16.45 | 4,000 | |
| $16.53 | +0.29 | +1.8% | $16.00 | $17.77 | $16.00 | 1,598,600 | |
| $16.24 | -0.18 | -1.1% | $16.17 | $16.80 | $16.00 | 125,200 | |
| $16.42 | +0.08 | +0.5% | $16.48 | $16.84 | $16.05 | 24,600 | |
| $16.34 | -0.16 | -1.0% | $16.40 | $16.90 | $16.30 | 30,800 | |
| $16.50 | +0.05 | +0.3% | $16.54 | $16.54 | $16.15 | 20,600 | |
| $16.45 | +0.01 | +0.1% | $16.59 | $16.90 | $16.45 | 28,200 | |
| $16.44 | -0.29 | -1.7% | $16.90 | $16.93 | $16.41 | 101,400 | |
| $16.73 | +0.37 | +2.3% | $16.45 | $16.73 | $16.37 | 41,600 | |
| $16.36 | +0.07 | +0.4% | $16.33 | $16.70 | $16.10 | 105,200 | |
| $16.29 | -0.37 | -2.2% | $16.46 | $16.51 | $16.16 | 86,600 | |
| $16.66 | -0.34 | -2.0% | $17.02 | $17.02 | $16.66 | 29,800 | |
| $17.00 | -0.19 | -1.1% | $17.01 | $17.47 | $17.00 | 11,200 | |
| $17.19 | +0.37 | +2.2% | $16.77 | $17.50 | $16.76 | 31,200 | |
| $16.82 | -0.28 | -1.6% | $17.13 | $17.40 | $16.80 | 78,000 | |
| $17.10 | +0.22 | +1.3% | $17.20 | $17.50 | $17.10 | 77,600 | |
| $16.88 | -0.09 | -0.5% | $16.97 | $17.00 | $16.53 | 8,200 | |
| $16.97 | +0.19 | +1.1% | $16.78 | $17.04 | $16.58 | 47,400 | |
| $16.78 | +0.38 | +2.3% | $17.30 | $17.30 | $16.68 | 154,000 |
- Ticker
- HKEX:2509
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 13, 2026
Supplemental agreement to the CDMO services framework agreement and revision of annual cap and renewal of annual caps for continuing connected transactions
Latest deck · August 2026
H1 2026 Earnings Presentation
Earnings · 32 slides
Latest news
Supplemental agreement to the CDMO services framework agreement and revision of annual cap and renewal of annual caps for continuing connected transactions
Nov 13, 2026
Closed $14.40 (-2.0%) on Nov 16, 2026
List of directors and their roles and functions
Nov 13, 2026
Closed $14.40 (-2.0%) on Nov 16, 2026
(1) Poll results of the extraordinary general meeting held on November 13, 2026; (2) appointment of non-executive director; and (3) change in composition of board committee
Nov 13, 2026
Closed $14.40 (-2.0%) on Nov 16, 2026
Voluntary announcement exclusive license agreement with caldera therapeutics for a preclinical bispecific antibody program targeting TL1A and IL-17
Nov 5, 2026
Closed $14.33 (-3.2%) on Nov 6, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 5, 2026
Closed $14.33 (-3.2%) on Nov 6, 2026
Documents on Display
Oct 27, 2026
Closed $15.18 (-6.4%) on Oct 28, 2026
Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026
Oct 27, 2026
Closed $15.18 (-6.4%) on Oct 28, 2026
Notice of the 2026 first extraordinary general meeting
Oct 27, 2026
Closed $15.18 (-6.4%) on Oct 28, 2026
(1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting
Oct 27, 2026
Closed $15.18 (-6.4%) on Oct 28, 2026
Announcement book closure period for extraordinary general meeting
Oct 26, 2026
Closed $16.21 (-2.3%) on Oct 27, 2026
Qyuns Therapeutics Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 16 in all · newest Nov 13, 2026 · oldest 2025
- Decks
- 5 decks · latest August 2026
Where Qyuns Therapeutics Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2509 荃信生物 · Home listing · This page | HKEX | Hong Kong | HKD |
| OTC:QYUNF | OTC | United States | USD |
Valuation
P/E 4.5× against a median of 15.3×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.98B HKD
- P/E
- 4.5×
- EV/sales
- 2.5×
- EV/EBITDA
- 4.2×
- Price/book
- 2.9×
- Gross margin
- 88.6%
- Operating margin
- 54.5%
- Net margin
- 53.3%
- Debt to equity
- 0.8×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509 | US$370.7M | US$380.5M | 4.5× | 2.5× | 4.2× | 2.9× | 53.3% | 0.8× | n/a |
| Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378 | US$387.5M | US$316.0M | n/a | n/a | n/a | 4.1× | n/a | 0.1× | n/a |
| Opus Genetics, Inc. · NASDAQ:IRD | US$385.7M | US$332.3M | n/a | 42.0× | n/a | 10.0× | n/a | 0.9× | 1.01 |
| Eupraxia Pharmaceuticals, Inc. · TSX:EPRX | US$384.3M | US$252.7M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.53 |
| Hinova Pharmaceuticals, Inc. Class A · SSE:688302 | US$381.1M | US$285.9M | n/a | 23.0× | n/a | 2.6× | −167.3% | 0.1× | n/a |
| Rezolute, Inc. · NASDAQ:RZLT | US$379.2M | US$289.9M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.28 |
| Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT | US$378.8M | US$359.8M | n/a | 1.3× | n/a | n/a | −30.2% | n/a | 1.08 |
| Puma Biotechnology Inc · NASDAQ:PBYI | US$364.5M | US$255.9M | 15.3× | 1.1× | 5.8× | 2.5× | 10.3% | 0.0× | 0.88 |
| PureTech Health PLC · LSE:PRTC | US$364.3M | US$160.3M | n/a | 34.4× | n/a | 0.9× | n/a | 0.1× | n/a |
| Lumosa Therapeutics Co Ltd · TPEX:6535 | US$362.3M | US$343.1M | n/a | 329× | n/a | 9.7× | n/a | 0.0× | n/a |
| Aspen Neuroscience, Inc. · NASDAQ:ASPE | US$361.2M | US$288.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$379.0M | US$289.3M | 15.3× | 28.7× | 5.8× | 3.5× | −30.2% | 0.0× | 1.08 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.00 HKD · Analysts' mean
- EPS, year to Dec 2026
- 1.22 · 2 analysts
- Revenue, year to Dec 2026
- 628.5M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hu Yanbao | Board Secretary and Joint Company Secretary |
| Lin Weidong | Executive Director and Deputy General Manager of Our Company |
| Qiu Jiwan | Executive Director,Chairman of Our Board and General Manager of Our Company |
| Wu Yiliang | Executive Director and General Manager of Cellularforce |
Board
| Director | Role |
|---|---|
| Qiu Jiwan | Executive Director,Chairman of Our Board and General Manager of Our Company |
| Hu Yanbao | Board Secretary and Joint Company Secretary |
| Lin Weidong | Executive Director and Deputy General Manager of Our Company |
| Wu Yiliang | Executive Director and General Manager of Cellularforce |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 32 slides | August 2026 |
| FY2025 Earnings Presentation | Earnings | 34 slides | Mar 31, 2026 |
| H1 2025 Earnings Presentation | Earnings | 31 slides | Aug 19, 2025 |
| FY2024 Earnings Presentation | Earnings | 34 slides | Mar 31, 2025 |
| H1 2024 Earnings Presentation | Earnings | 31 slides | Aug 16, 2024 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 786.1M | 158.8M | 14.8M | 9.66M | 21.3M |
| Cost of revenue | 121.4M | 66.6M | 35.7M | 35.5M | 30.9M |
| Gross profit | 664.7M | 92.2M | -33.0M | 9.66M | -9.56M |
| Research and development | 239.2M | 334.3M | 364.4M | 257.2M | 151.9M |
| Selling, general and administrative | 99.8M | 115.9M | 164.6M | 76.6M | 24.0M |
| Operating income | 319.7M | -326.4M | -504.5M | -293.7M | -168.6M |
| Depreciation and amortization | 32.1M | 32.7M | 32.3M | 30.5M | 25.6M |
| EBITDA | 351.8M | -293.7M | -472.2M | -263.1M | -143.0M |
| Interest expense | 21.6M | 23.4M | 16.8M | 18.7M | 17.8M |
| Income before tax | 299.4M | -349.8M | -521.3M | -312.4M | -426.5M |
| Income tax | 71.1K | -73.0K | -73.0K | -73.0K | -73.0K |
| Net income | 306.3M | -335.6M | -507.7M | -298.2M | -411.0M |
| Earnings per share, basic | 1.37 | -1.53 | -2.47 | -1.34 | -1.85 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 962.2M | 360.7M | 216.3M | 213.1M | 218.1M |
| Short-term investments | 80.3M | 195.4M | 160.4M | 450.3M | 402.4M |
| Receivables | 19.9M | 26.9M | 364.0K | 662.0K | 354.0K |
| Inventory | 38.1M | 3.34M | 3.77M | 0 | |
| Current assets | 1.12B | 616.7M | 418.3M | 714.0M | 648.3M |
| Property, plant and equipment | 334.1M | 363.2M | 389.0M | ||
| Total assets | 1.60B | 983.9M | 795.6M | 1.16B | 1.07B |
| Accounts payable | 96.8M | 110.9M | 73.0M | 19.1M | 12.6M |
| Current liabilities | 504.0M | 430.2M | 251.8M | 122.2M | 69.7M |
| Long-term debt | 399.4M | 315.1M | 224.4M | 232.5M | 274.0M |
| Total debt | 580.3M | 527.6M | 346.1M | 295.3M | 290.3M |
| Total liabilities | 921.6M | 762.8M | 494.6M | 373.7M | 363.3M |
| Shareholders' equity | 694.3M | 229.0M | 294.8M | 641.7M | 670.4M |
| Shares outstanding | 223.7M | 219.4M | 205.7M | 222.1M | 222.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | 399.8M | -186.1M | -300.7M | -225.2M | -122.6M |
| Capital spending | -7.62M | -1.76M | -7.95M | -26.5M | -71.0M |
| Free cash flow | 392.2M | -187.9M | -308.6M | -301.7M | -228.6M |
| Cash from investing | 118.7M | -25.2M | 243.1M | -5.70M | -247.4M |
| Cash from financing | 93.7M | 351.8M | 61.2M | 211.5M | 281.5M |
| Share buybacks | -27.2M | 196.5M | 29.5M | 228.0M | |
| Change in cash | 601.1M | 144.4M | 3.21M | -4.96M | -91.2M |
Filings
All 15 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL STUDY RESULTS OF OTURKIBART (QX005N) FOR TREATMENT OF PRURIGO NODULARIS PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT EADV 2026 | Oct 1, 2026 | Other filings | HKEX |
| LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | Sep 22, 2026 | List of directors | HKEX |
| CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT; AND RESIGNATION AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | Sep 22, 2026 | Management or board change | HKEX |
| 2026 INTERIM REPORT | Sep 21, 2026 | Interim report | HKEX |
Cap table
Built by 6ix from Qyuns Therapeutics Co., Ltd. Class H’s releases
- Common shares
- 223,369,200
- Fully diluted
- 223,369,200
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 223,369,200 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 223,369,200 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Qiu Jiwan | Executive Director,Chairman of Our Board and General Manager of Our Company · Since at least Jun 16, 2025 |
Log in to ask 6ix AI your own questions about Qyuns Therapeutics Co., Ltd.